General Information of Drug (ID: DM5SD9E)

Drug Name
Tricyclic benzimidazole derivative 1 Drug Info
Synonyms PMID26161698-Compound-21
Cross-matching ID
PubChem CID
75201489
TTD Drug ID
DM5SD9E

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Preclinical Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SEL120 DMHCUZV Acute myeloid leukaemia 2A60 Phase 1 [2]
Macrocycle derivative 14 DMXSRPH N. A. N. A. Patented [1]
CCT251545 DMNA9KW Colorectal cancer 2B91.Z Preclinical [3]
Oxindole 94 DMPFD6Y Pain MG30-MG3Z Investigative [4]
Oxindole 16 (compound 3) DMM5208 Discovery agent N.A. Investigative [4]
Drug Name Drug ID Indication ICD 11 Highest Status REF
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [5]
Roscovitine derivative 1 DMD1G3Z N. A. N. A. Patented [1]
4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN N. A. N. A. Patented [1]
Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW N. A. N. A. Patented [1]
Naphthyridine and isoquinoline derivative 1 DMTGIP7 N. A. N. A. Patented [1]
PMID26161698-Compound-18 DM6JVR5 N. A. N. A. Patented [1]
Flavonoid derivative 7 DM6A9UR N. A. N. A. Patented [1]
L-751250 DMOERXK Obesity 5B81 Preclinical [4]
Olomoucine DMNAFG1 N. A. N. A. Terminated [4]
aloisine A DM5U1LN Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flavopiridol DMKSUOI Acute myeloid leukaemia 2A60 Phase 2 [7]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [8]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [9]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
BTX-A51 DMC8XHQ Advanced solid tumour 2A00-2F9Z Phase 1 [11]
CYC065 DM9ODT6 Lymphoma 2A80-2A86 Phase 1 [7]
AZD4573 DMOYPTK Haematological malignancy 2B33.Y Phase 1 [7]
TP-1287 DM3Z07E Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
VIP-152 DMBQ5OL Chronic lymphocytic leukaemia 2A82.0 Phase 1 [13]
AZD7503 DM8XJD2 Non-alcoholic steatohepatitis DB92.1 Phase 1 [14]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [8]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [15]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [8]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [16]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [9]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [1]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [18]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [19]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [8]
Samuraciclib DM54FQA Breast cancer 2C60-2C65 Phase 1/2 [20]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
BTX-A51 DMC8XHQ Advanced solid tumour 2A00-2F9Z Phase 1 [11]
SY-1365 DMK48PM Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
LY3405105 DMB51K2 Solid tumour/cancer 2A00-2F9Z Phase 1 [21]
SY-5609 DMNW3LH Solid tumour/cancer 2A00-2F9Z Phase 1 [22]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [1]
Roscovitine derivative 1 DMD1G3Z N. A. N. A. Patented [1]
Pyrazolo-triazine derivative 2 DML6V78 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 1 (CDK1) TTH6V3D CDK1_HUMAN Inhibitor [1]
Cyclin-dependent kinase 5 (CDK5) TTL4Q97 CDK5_HUMAN Inhibitor [1]
Cyclin-dependent kinase 7 (CDK7) TTQYF7G CDK7_HUMAN Inhibitor [1]
Cyclin-dependent kinase 8 (CDK8) TTBJR4L CDK8_HUMAN Inhibitor [1]
Cyclin-dependent kinase 9 (CDK9) TT1LVF2 CDK9_HUMAN Inhibitor [1]

References

1 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
2 Clinical pipeline report, company report or official report of Ryvu Therapeutics.
3 Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353-377.
4 Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
5 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
6 Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
9 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
10 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
11 Clinical pipeline report, company report or official report of BioTheryX.
12 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
13 VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023 Feb;37(2):326-338.
14 ClinicalTrials.gov (NCT05560607) An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
15 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
16 P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
17 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
18 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
19 Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
20 The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023 Jun;128(12):2326-2337.
21 CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.
22 Clinical pipeline report, company report or official report of Syros Pharmaceuticals.